نتائج البحث

1

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers

المؤلفون: Matthew Hitron, Michael D. Karol, Marjie L. Hard, Xiaoshu Dai, Colleen F. Mclaughlin, Scott J. Brantley, Matthew T. Goulet

المصدر: Clinical Pharmacology in Drug Development

مصطلحات موضوعية: Male, Organic anion transporter 1, Flurbiprofen, Pharmaceutical Science, Administration, Oral, Pharmacology, 030226 pharmacology & pharmacy, Dextromethorphan, 0302 clinical medicine, phase 1 trial, Cytochrome P-450 Enzyme System, ATP Binding Cassette Transporter, Subfamily G, Member 2, Pharmacology (medical), Drug Interactions, Rosuvastatin Calcium, Omeprazole, biology, Hydroxybupropion, Articles, Repaglinide, Healthy Volunteers, Neoplasm Proteins, 030220 oncology & carcinogenesis, Female, breast cancer resistance protein transporter, medicine.drug, Half-Life, Adult, drug‐drug interactions, cytochrome P450, Midazolam, napabucasin, Original Manuscript, 03 medical and health sciences, Young Adult, Pharmacokinetics, Caffeine, medicine, Humans, Bupropion, Benzofurans, business.industry, Gene Expression Regulation, biology.protein, business, Naphthoquinones

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd249a6a220f2dc5c28a0e4212bd82e9Test
http://europepmc.org/articles/PMC8453567Test

2

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

المؤلفون: Victor Moreno, Noelia Nebot, Emmanuel Bouillaud, Dung-Yang Lee, Eva Muñoz-Couselo, Christina S. Won, Eduard Gasal

المساهمون: Institut Català de la Salut, [Nebot N, Lee DY, Gasal E] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. [Won CS] Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA. [Moreno V] START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Muñoz-Couselo E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Bouillaud E] Novartis Pharma AG, Basel, Switzerland, Vall d'Hebron Barcelona Hospital Campus

المصدر: Clinical Pharmacology in Drug Development
Scientia

مصطلحات موضوعية: Male, CYP3A4, CYP3A, Pharmaceutical Science, Pharmacology, 030226 pharmacology & pharmacy, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::interacciones farmacológicas [FENÓMENOS Y PROCESOS], 0302 clinical medicine, Oximes, Medicine, fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::farmacocinética [FENÓMENOS Y PROCESOS], Cytochrome P-450 CYP3A, Pharmacology (medical), Drug Interactions, Rosuvastatin Calcium, OATP, Liver-Specific Organic Anion Transporter 1, Imidazoles, Articles, Middle Aged, Other subheadings::/pharmacology [Other subheadings], Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacokinetics [PHENOMENA AND PROCESSES], 030220 oncology & carcinogenesis, Area Under Curve, Female, pharmacokinetics, medicine.drug, Adult, Midazolam, Cmax, Original Manuscript, transporters, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], 03 medical and health sciences, Solute Carrier Organic Anion Transporter Family Member 1B3, Pharmacokinetics, Humans, Rosuvastatin, dabrafenib, Protein Kinase Inhibitors, drug interaction, Farmacocinètica, business.industry, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Dabrafenib, Drug interaction, Medicaments - Interacció, Proteïnes quinases - Inhibidors, Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Interactions [PHENOMENA AND PROCESSES], Otros calificadores::/farmacología [Otros calificadores], business